Patient Leaflet Updated 20-Oct-2026 | Takeda UK Ltd
Prostap PD DCS
PROSTAP® PD DCS
1.88 mg Powder and Solvent for Prolonged-release Suspension for Injection in Pre-filled Syringe
leuprorelin acetate
1. What PROSTAP PD DCS is and what it is used for
2. What you need to know before your child is given PROSTAP PD DCS
3. How to use PROSTAP PD DCS
4. Possible side effects
5. How to store PROSTAP PD DCS
6. Contents of the pack and other information
PROSTAP PD DCS is a synthetic hormone which can be used to reduce the levels of testosterone and oestrogen (sex steroids) circulating in the body.
PROSTAP PD DCS is used to treat premature puberty which is caused by a release of certain hormones from the pituitary gland (central precocious puberty) in girls under 9 years of age and boys under 10 years of age with a body weight of less than 20 kg.
Your doctor will make a precise diagnosis of central precocious puberty.
When your child begins treatment with PROSTAP PD DCS, existing symptoms may initially get worse as a result of levels of sex steroids in the body increasing. These worsening symptoms usually subside with continued use of PROSTAP PD DCS (see section 4 for further information).
Severe skin rashes including Stevens-Johnson syndrome, Toxic Epidermal Necrolysis (SJS/TEN) have been reported in association with leuprorelin. Stop using leuprorelin and seek medical attention immediately if you notice any of the symptoms related to these serious skin reactions described in section 4.
Talk to your doctor or nurse before your child is given PROSTAP PD DCS:
In girls with central precocious puberty:
Please tell your doctor or pharmacist if your child is taking or has recently taken any other medicines, including medicines obtained without a prescription.
PROSTAP PD DCS must not be given to pregnant or breast-feeding girls (see also section “Do not use PROSTAP PD DCS’).
Your child may feel dizzy, have blurred vision or difficulty focussing his/her eyes. If these happen it may be dangerous to do things such as use machines, ride a bike or a horse or climb trees.
This medicine contains 1 mg of polysorbate 80 in each ml of suspension which is equivalent to 1 mg/ml. Polysorbates may cause allergic reactions. Tell your doctor if your child has any known allergies.
This medicine contains less than 1 mmol sodium (23 mg) per injection, that is to say it is essentially ‘sodium-free’.
Your doctor or nurse will give your child an injection of PROSTAP PD DCS. The injection should be given immediately after it has been prepared. The injection will normally be given in the arm, thigh or abdomen. The injection site should be varied at regular intervals.
Your child will normally be given an injection once a month.
The dosing scheme needs to be adapted individually.
The recommended starting dose is dependent on body weight:
a) Children with a body weight less than 20 kg
Taking into account the clinical activity of the central precocious puberty in these rare cases, the following applies:
Unless prescribed otherwise, 1 ml PROSTAP PD DCS (1.88 mg leuprorelin acetate) is administered once a month under the skin of e.g. abdomen, bottom or thigh as a single injection. Your doctor will monitor your child’s weight gain.
b) Children with a body weight 20 kg or more
Other forms of leuprorelin may be more suitable, such as 1 ml PROSTAP SR (3.75 mg leuprorelin acetate) administered once a month under the skin.
Depending on the central precocious puberty activity, your doctor may increase the dosage in the presence of inadequate suppression (e.g. vaginal bleeding). Your doctor will determine the minimal effective dose with the help of a blood test.
The duration of treatment depends on the clinical signs at the start of treatment or during the course of treatment and may be decided by your doctor together with the legal guardian and, if appropriate, child being treated. Your doctor will determine the bone age of your child at regular intervals.
In girls with bone age of older than 12 years and boys with bone age of older than 13 years your doctor will consider discontinuing the treatment, depending on the clinical effects.
In girls, pregnancy should be excluded before the start of treatment. The occurrence of pregnancy during treatment cannot be generally excluded. In such cases, please talk to your doctor.
The therapy is a long-term treatment, adjusted individually. Please arrange with your doctor that PROSTAP PD DCS is administered as precisely as possible in regular monthly periods. An exceptional delay of the injection date for a few days (30 ± 2 days) does not influence the result of the therapy.
As soon as you realise your child has missed an injection, contact your doctor who will be able to give your child the next injection.
Your doctor will talk to you and your child before stopping treatment.
If you have any further questions on the use of this medicine, ask your doctor or nurse.
Like all medicines, PROSTAP PD DCS can cause side effects, although not everybody gets them.
At the beginning of treatment, a temporary rise in the sex hormone levels occurs, followed by a fall to values within the prepuberty range. Due to this effect, side effects may occur particularly at the start of treatment.
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
Very rare (may affect up to 1 in 10,000 people):
Not known (frequency cannot be estimated from the available data):
In general, if vaginal bleeding (spotting) occurs with continued treatment (after possible withdrawal bleeding in the first month of treatment), this may be a sign of potential underdosage. Please tell your doctor if vaginal bleeding occurs.
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow Card Scheme. Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the packaging. The expiry date refers to the last day of that month.
Do not refrigerate or freeze.
Store in the original container in order to protect from light.
Once mixed with the Sterile Solvent, the suspension must be used immediately.
If the pack has been opened or damaged, return it to your pharmacist.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
PROSTAP PD DCS should only be administered by your doctor or a nurse who will also take care of the preparation of the product.
PROSTAP PD DCS is a prolonged release powder for use in an injection.
The solventis a clear liquid, which is mixed with the PROSTAP PD DCS Powder before injection.
Each pack contains a pre-filled dual chamber syringe containing 1.88 mg leuprorelin acetate powder in the front chamber and 1 ml of solvent in the rear chamber, a syringe needle fitted with a safety device and one syringe plunger.
This leaflet does not contain the complete information about your medicine. If you have any questions or you are not sure about anything you should ask your doctor or nurse who can give you more information. The information in this leaflet applies only to PROSTAP PD DCS.
This leaflet was last revised in October 2026.
* Registered Trademark of Takeda
[Takeda logo]
This leaflet can be made available in large print, audio or Braille on request. Contact 0800 198 5000 to request this, quoting the following number: 16189/0038
1 Kingdom Street, London, W2 6BD, UK
+44 (0)3333 000 181
www.takeda.com/en-gb/
+44 (0)3333 000 181